Resverlogix Notice of Conference Call & Webcast May 2, 2008
The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. (PR Newswire)
Major discovery in the treatment of aortic valve stenosis Apr 19, 2008
The animals were then divided into two groups: a control group given injections of a neutral solution, and a group treated for two weeks with injections of a drug based on raising the good cholesterol (ApoA-I mimetic peptide). The findings were particularly interesting, since after only 14 days of treatment, the aortic valve opening in subjects had returned again to almost normal in the treated group, whereas it had improved by a mere 13 percent by eliminating the high-fat diet in the control... (EurekAlert!)
The Montreal Heart Institute Research Centre makes a major discovery in the treatment of aortic valve stenosis Apr 18, 2008
The animals were then divided into two groups: a control group given injections of a neutral solution, and a group treated for two weeks with injections of a drug based on raising the "good cholesterol" (ApoA-I mimetic peptide). The researchers chose the rabbit model for this study, as it is the best model known today for drawing parallels with the human disease, which is often associated with aortic valve calcification. (Canada Newswire)
Very High 'Good' Cholesterol Might Be Bad Feb 6, 2008
On the other hand, apolipoprotein A-I or apoA-I -- which like HDL cholesterol has been linked to a reduced heart disease risk -- continues to show this association at very high levels, according to the report in the Journal of the American College of Cardiology. To gauge the impact of very high levels of HDL cholesterol and apoA-I on cardiovascular risk, Dr. John J. P. Kastelein from the Academic Medical Center in Amsterdam, the Netherlands, and colleagues analyzed data from the so-called IDEAL... (MEDLINEplus)
